SALT
LAKE CITY, July 29, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that it is hosting a booth at the Association for
Diagnostics & Laboratory Medicine (ADLM) annual meeting and
expo held July 28-August 1, 2024, in
Chicago, IL.
Co-Dx will also be holding a special company presentation to
discuss the role of its new at-home and point-of-care Co-Dx™ PCR
platform* in closing the global diagnostics gap for an array of
potential indications, including tuberculosis (TB). The platform's
first FDA 510(k) application, for a COVID-19 test, was submitted in
mid-June. Other tests in the pipeline are expected to meet the
diverse needs of a global market.
The presentation will take place in Room S102D at 2:00 PM local time on Tuesday, July 30, and will include Co-Dx CEO
Dwight Egan and Co-Dx Executive VP
of Business Development Joseph Featherstone addressing how the
company is taking an advanced position in the worldwide initiative
to end TB by 2030.
In addition to the Company's current and planned pipeline of
testing products, both for the new platform and for its existing
customer base of distributors and clinical laboratories around the
world, the Co-Dx booth will showcase the Co-Dx PCR Pro™ instrument,
which is currently under FDA review and is not available for sale.
The Company will also be presenting a scientific poster, #B-192, at
1:30-2:30 on July
31st.
Attendees interested in learning more are invited to visit the
Company at Booth 2879. Information about the ADLM conference may be
found here.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™,
mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not available for sale.
The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently
under review by the FDA and are not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the role of our new
at-home and point-of-care Co-Dx™ PCR platform in closing the global
diagnostics gap for an array of indications. Actual results
may differ materially from those contemplated or anticipated by
such forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-and-discuss-advancing-pocotc-diagnostics-at-adlm-2024-in-chicago-302208366.html
SOURCE Co-Diagnostics
